Drugs / Allogeneic adipose-derived stem cells
Allogeneic adipose-derived stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05017298 | Nov 2024 overdue | COVID-19 | Celltex Therapeutics Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic adipose-derived stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05017298 ↗ |
| Modality | Cell therapy | “Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells” NCT05017298 ↗ |
| Route | Intravenous | “using intravenous injection of allogeneic adipose stem cells” NCT05017298 ↗ |